Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28604267 | 0.77 | GAA (0.44) | MAPTGAA | |
| SCHEMBL28658376 | 0.75 | MAPT (0.41) | MAPTGAASMN1; SMN2RAB9AP2RX4 | |
| SCHEMBL9164081 | 0.75 | MAPT (0.41) | MAPTGAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL1249108 | 0.75 | MAPT (0.54) | MAPTGAASMN1; SMN2RAB9AP2RX4 | |
| SCHEMBL27552412 | 0.74 | MAPT (0.40) | MAPTGAASMN1; SMN2RAB9AP2RX4 | |
| SCHEMBL10880606 | 0.74 | GAA (0.40) | MAPTGAAMEN1MAPK1KMT2A | |
| SCHEMBL3193087 | 0.73 | ALOX15 (0.42) | MAPTGAASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL27283728 | 0.71 | MAPT (0.45) | MAPTGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL460837 | 0.71 | MAPT (0.54) | MAPTGAASMN1; SMN2RAB9AP2RX4 | |
| SCHEMBL8769697 | 0.71 | MAPT (0.54) | MAPTGAASMN1; SMN2RAB9AP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1038099-A | Alpha-adrenergic aceptor antagonist | SMITHKLINE BECKMAN CORP (US) | 1989-12-20 | — | — | CN | claimed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| US-7022694-B2 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1406902-B1 | HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1406902-A1 | HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003006466-A1 | HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| EP-0230755-B1 | 1-PHENYL-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-05-16 | — | — | EP | disclosed |
| CN-1039810-A | ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORP (US) | 1990-02-21 | — | — | CN | disclosed |
| CN-1038099-A | Alpha-adrenergic aceptor antagonist | SMITHKLINE BECKMAN CORP (US) | 1989-12-20 | — | — | CN | disclosed |
| US-4707483-A | 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0230755-A1 | 1-Phenyl-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060458-A1 | Indoles and indolines having 5-HT activity | TPH1, HTR5A, TPH2 | MAPT 2607/4885GAA 4374/4885SMN1; SMN2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.